Targeting BCL2-Proteins for the Treatment of Solid Tumours

Overview

Journal Adv Med

Publisher Wiley

Specialty General Medicine

Date 2015 Nov 12

PMID 26556430

Citations 66

Authors

Meike Vogler

Affiliations

Soon will be listed here.

Abstract

Due to their central role in the regulation of apoptosis, the antiapoptotic BCL2-proteins are highly promising targets for the development of novel anticancer treatments. To this end, several strategies have been developed to inhibit BCL2, BCL-XL, BCL-w, and MCL1. While early clinical trials in haematological malignancies demonstrated exciting single-agent activity of BCL2-inhibitors, the response in solid tumours was limited, indicating that, in solid tumours, different strategies have to be developed in order to successfully treat patients with BCL2-inhibitors. In this review, the function of the different antiapoptotic BCL2-proteins and their role in solid tumours will be discussed. In addition, a comprehensive analysis of current small molecules targeting these antiapoptotic BCL2-proteins (e.g., ABT-737, ABT-263, ABT-199, TW-37, sabutoclax, obatoclax, and MIM1) will be provided including a discussion of the results of any clinical trials. This analysis will summarise the potential of BCL2-inhibitors for the treatment of solid tumours and will unravel novel approaches to utilise these inhibitors in clinical applications.

Citing Articles

Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer.

Zapata Dongo R, Fontana D, Mologni L, Faya Castillo J, Infante Varillas S PLoS One. 2025; 20(1):e0308747.

PMID: 39836700 PMC: 11750102. DOI: 10.1371/journal.pone.0308747.

Ergotamine Targets KIF5A to Facilitate Anoikis in Lung Adenocarcinoma.

Bao B, Yu X, Zheng W, Sun J Clin Respir J. 2024; 18(11):e70020.

PMID: 39517115 PMC: 11549061. DOI: 10.1111/crj.70020.

BCL-X-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.

Judd A, Bawa B, Buck W, Tao Z, Li Y, Mitten M Sci Adv. 2024; 10(40):eado7120.

PMID: 39365864 PMC: 11451551. DOI: 10.1126/sciadv.ado7120.

Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family.

Boroujeni A, Ates-Alagoz Z Anticancer Agents Med Chem. 2024; 25(3):164-178.

PMID: 39313901 DOI: 10.2174/0118715206320224240910054728.

MERTK Is a Potential Therapeutic Target in Ewing Sarcoma.

Smart S, Yeung T, Santos M, McSwain L, Wang X, Frye S Cancers (Basel). 2024; 16(16).

PMID: 39199601 PMC: 11352666. DOI: 10.3390/cancers16162831.

References

Kitada S, Leone M, Sareth S, Zhai D, Reed J, Pellecchia M . Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 2003; 46(20):4259-64. DOI: 10.1021/jm030190z. View

Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A . BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007; 12(2):171-85. DOI: 10.1016/j.ccr.2007.07.001. View

Boise L, Gonzalez-Garcia M, Postema C, Ding L, LINDSTEN T, Turka L . bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993; 74(4):597-608. DOI: 10.1016/0092-8674(93)90508-n. View

Wan K, Chan S, Sukumaran S, Lee M, Yu V . Chelerythrine induces apoptosis through a Bax/Bak-independent mitochondrial mechanism. J Biol Chem. 2008; 283(13):8423-33. PMC: 2417179. DOI: 10.1074/jbc.M707687200. View

McIlwain D, Berger T, Mak T . Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2013; 5(4):a008656. PMC: 3683896. DOI: 10.1101/cshperspect.a008656. View

Tahir S, Yang X, Anderson M, Morgan-Lappe S, Sarthy A, Chen J . Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007; 67(3):1176-83. DOI: 10.1158/0008-5472.CAN-06-2203. View

Rodrigue-Gervais I, Saleh M . Caspases and immunity in a deadly grip. Trends Immunol. 2012; 34(2):41-9. DOI: 10.1016/j.it.2012.09.005. View

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

Song T, Chang X, Zhang Z, Liu Y, Shen X . S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak. J Pharmacol Sci. 2012; 119(4):330-40. DOI: 10.1254/jphs.12103fp. View

10.

Moulding D, Quayle J, Hart C, Edwards S . Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. Blood. 1998; 92(7):2495-502. View

11.

Choi E, Jung J, Lee J, Park J, Cho N, Cho S . Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model. Cancer Lett. 2012; 328(1):65-72. DOI: 10.1016/j.canlet.2012.09.009. View

12.

Monaghan P, Robertson D, Amos T, Dyer M, Mason D, Greaves M . Ultrastructural localization of bcl-2 protein. J Histochem Cytochem. 1992; 40(12):1819-25. DOI: 10.1177/40.12.1453000. View

13.

Nguyen M, Marcellus R, Roulston A, Watson M, Serfass L, Murthy Madiraju S . Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A. 2007; 104(49):19512-7. PMC: 2148320. DOI: 10.1073/pnas.0709443104. View

14.

Hockenbery D, Zutter M, Hickey W, Nahm M, Korsmeyer S . BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A. 1991; 88(16):6961-5. PMC: 52213. DOI: 10.1073/pnas.88.16.6961. View

15.

Krajewska M, Kitada S, Winter J, Variakojis D, Lichtenstein A, Zhai D . Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res. 2008; 14(10):3011-21. PMC: 4171052. DOI: 10.1158/1078-0432.CCR-07-1955. View

16.

Kirsh E, Baunoch D, Stadler W . Expression of bcl-2 and bcl-X in bladder cancer. J Urol. 1998; 159(4):1348-53. View

17.

Wang G, Nikolovska-Coleska Z, Yang C, Wang R, Tang G, Guo J . Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006; 49(21):6139-42. DOI: 10.1021/jm060460o. View

18.

Hwang J, Kuruvilla J, Mendelson D, Pishvaian M, Deeken J, Siu L . Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res. 2010; 16(15):4038-45. PMC: 3703245. DOI: 10.1158/1078-0432.CCR-10-0822. View

19.

Beverly L, Varmus H . MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene. 2009; 28(9):1274-9. PMC: 2743088. DOI: 10.1038/onc.2008.466. View

20.

Krajewska M, Moss S, Krajewski S, Song K, Holt P, Reed J . Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res. 1996; 56(10):2422-7. View